CAJ | 학술논문

目的评估微波消融治疗原发性或复发性肺癌及转移性肺癌的临床疗效,探讨其安全性.方法回顾性分析2005年1月至2008年1月间在唐都医院胸外科住院的69例原发或复发性非小细胞肺癌及肺转移癌患者,观察其术后并发症,对不同大小肿瘤患者的术后3年内生存率及病死率进行比较.结果 ①术后并发症:共计26例患者出现并发症,其中13例气胸,5例咯血,2例血胸,3例肺炎,2例暂时性胸痛,2例低热,无皮肤烧伤.未发现针道种植,术后30 d内无患者死亡.②肿瘤直径＞4 cm患者的3年原位进展率与＜4 cm的2组患者之间差异有统计学意义；非小细胞肺癌、肺转移肿瘤患者的1、2和3年的总生存率分别为77.1％( 37/48)、43.7％ (21/48)、22.9％ (11/48)和52.4％( 11/21)、28.6％ (6/21)、14.3％ (3/21)；无癌生存率分别为72.9％ (35/48)、35.4％ (17/48)、12.5％ (6/48)和47.6％( 10/21)、19.0％ (4/21)、9.5％(2/21).非小细胞肺癌和肺转移癌的总生存率及病死率之间差异有统计学意义(P＜0.05).结论肺部肿瘤微波消融是安全、有效的治疗方法,可延长癌症患者生存期、明显提高患者生存率.
목적 평고미파소융치료원발성혹복발성폐암급전이성폐암적림상료효,탐토기안전성.방법 회고성분석2005년1월지2008년1월간재당도의원흉외과주원적69례원발혹복발성비소세포폐암급폐전이암환자,관찰기술후병발증,대불동대소종류환자적술후3년내생존솔급병사솔진행비교.결과 ①술후병발증:공계26례환자출현병발증,기중13례기흉,5례각혈,2례혈흉,3례폐염,2례잠시성흉통,2례저열,무피부소상.미발현침도충식,술후30 d내무환자사망.②종류직경＞4 cm환자적3년원위진전솔여＜4 cm적2조환자지간차이유통계학의의；비소세포폐암、폐전이종류환자적1、2화3년적총생존솔분별위77.1％( 37/48)、43.7％ (21/48)、22.9％ (11/48)화52.4％( 11/21)、28.6％ (6/21)、14.3％ (3/21)；무암생존솔분별위72.9％ (35/48)、35.4％ (17/48)、12.5％ (6/48)화47.6％( 10/21)、19.0％ (4/21)、9.5％(2/21).비소세포폐암화폐전이암적총생존솔급병사솔지간차이유통계학의의(P＜0.05).결론 폐부종류미파소융시안전、유효적치료방법,가연장암증환자생존기、명현제고환자생존솔.
Objective To evaluate the clinical curative effect in treating primary lung cancer and metastatic lung cancer with microwave ablation.Methods The data of 69 cases with primary or recurrent non-small-cell lung cancer and metastatic lung cancer patients from January 2005 to January 2008 in our department were retrospectively analyzed.The survival rates and mortality rates within three years after operation were compared among different sizes of tumor.Results There were totally 26 patients with complications,including 13 cases with pneumothorax,5 cases with hemoptysis,2 cases with hemothorax,3 cases with pulmonitis,2 cases with temporary pain and 2 cases with low fever.No needle track implantation was found and no patients died within postoperatively 30 days.There were significant differences of tumors more than 4 cm and less than 4 cm in 3-year follow-ups.1,2,and 3-year overall survival rates of patients with non-small cell lung cancer patients and lung metastases were 77.1％ (37/48),43.7％ (21/48),22.9％ ( 11/48 ),and 52.4％ ( 11/21 ),28.6％ (6/21),14.3％ ( 3/21 ) ; cancer-free survival rates were 72.9％ ( 35/48 ),35.4％ (17/48),12.5％ (6/48) and 47.6％ ( 10/21 ),19.0％ (4/21),9.5％ ( 2/21 )respectively.The overall survival rates and cancer-free survival rates were significantly different between non-small cell lung cancer and lung metastases.Conclusion Microwave ablation of lung tumors is a safe and effective method to prolong the survival time of the patients with primary lung cancer and metastatic lung cancer and can improve patients' survival rates.